Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia.
Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T, Maywald O, Reiter A, Hossfeld DK, Huber C, Löffler H, Pralle H, Queisser W, Tobler A, Nerl C, Solenthaler M, Goebeler ME, Griesshammer M, Fischer T, Kremers S, Eimermacher H, Pfreundschuh M, Hirschmann WD, Lechner K, Wassmann B, Falge C, Kirchner HH, Gratwohl A. Hehlmann R, et al. Among authors: tobler a. Blood. 2007 Jun 1;109(11):4686-92. doi: 10.1182/blood-2006-11-055186. Epub 2007 Feb 22. Blood. 2007. PMID: 17317858 Free article. Clinical Trial.
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure.
Hehlmann R, Hochhaus A, Kolb HJ, Hasford J, Gratwohl A, Heimpel H, Siegert W, Finke J, Ehninger G, Holler E, Berger U, Pfirrmann M, Muth A, Zander A, Fauser AA, Heyll A, Nerl C, Hossfeld DK, Löffler H, Pralle H, Queisser W, Tobler A. Hehlmann R, et al. Among authors: tobler a. Blood. 1999 Dec 1;94(11):3668-77. Blood. 1999. PMID: 10572078 Free article. Clinical Trial.
Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O, Hasford J, Reiter A, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Griesshammer M, Nerl C, Kuse R, Tobler A, Eimermacher H, Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Weiss J, Meier CR, Kremers S, Labedzki L, Schmeiser T, Lohrmann HP, Heimpel H; German CML-Study Group. Hehlmann R, et al. Among authors: tobler a. Leukemia. 2003 Aug;17(8):1529-37. doi: 10.1038/sj.leu.2403006. Leukemia. 2003. PMID: 12886239 Clinical Trial.
Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia.
Maywald O, Pfirrmann M, Berger U, Breitscheidel L, Gratwohl A, Kolb HJ, Beelen DW, Tobler A, Metzgeroth G, Gnad SU, Hochhaus A, Hasford J, Hehlmann R, Reiter A; German CML Study Group; Swiss Group of Clinical Cancer Research. Maywald O, et al. Among authors: tobler a. Leukemia. 2006 Mar;20(3):477-84. doi: 10.1038/sj.leu.2404100. Leukemia. 2006. PMID: 16453005
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group.
Hehlmann R, Heimpel H, Hossfeld DK, Hasford J, Kolb HJ, Löffler H, Pralle H, Queisser W, Hochhaus A, Tichelli A, Fett W, Schmitz N, Reiter A, Griesshammer M, Pfeifer W, Bümler M, Kamp T, Tobler A, Eimermacher H, Kuse R, Berger U, Ansari H. Hehlmann R, et al. Among authors: tobler a. Bone Marrow Transplant. 1996 May;17 Suppl 3:S21-4. Bone Marrow Transplant. 1996. PMID: 8769695 Clinical Trial.
[Chronic myeloid leukemia--update].
Tobler A, Solenthaler M. Tobler A, et al. Ther Umsch. 2004 Feb;61(2):143-50. doi: 10.1024/0040-5930.61.2.143. Ther Umsch. 2004. PMID: 15018397 German.
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.
Proetel U, Pletsch N, Lauseker M, Müller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pfirrman M, Hochhaus A, Hasford J, Hehlmann R, Saußele S; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK). Proetel U, et al. Ann Hematol. 2014 Jul;93(7):1167-76. doi: 10.1007/s00277-014-2041-0. Ann Hematol. 2014. PMID: 24658964 Free PMC article. Clinical Trial.
Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia.
Buesche G, Freund M, Hehlmann R, Georgii A, Ganser A, Hecker H, Heimpel H, Fonatsch C, Heinze B, Pfirrmann M, Holgado S, Schmeil A, Tobler A, Hasford J, Buhr T, Kreipe HH; German CML Study Group. Buesche G, et al. Among authors: tobler a. Leukemia. 2004 Sep;18(9):1460-7. doi: 10.1038/sj.leu.2403451. Leukemia. 2004. PMID: 15284854
219 results